Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons.
The authors describe the development of a population pharmacokinetic model using NONMEM for itraconazole and its active metabolite hydroxyitraconazole in a Thai cohort of HIV-infected patients who were using itraconazole as an addition to their antiretroviral therapy. The data were best described with an open two-compartment model for both itraconazole and hydroxyitraconazole. The model adequately described the data and provided population pharmacokinetic parameters which were not different from those described for other populations. The authors found that concomitant use of co-trimoxazole leads to a reduced formation rate (-51%) of hydroxyitraconazole.
Koks
Cees H W
CH
Slotervaart Hospital, Department of Pharmacy and Pharmacology, Amsterdam, The Netherlands. apkko@slz.nl
Huitema
Alwin D R
AD
Kroon
Eugene D M B
ED
Chuenyam
Theshinee
T
Sparidans
Rolf W
RW
Lange
Joep M A
JM
Beijnen
Jos H
JH
D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001499:Bayes Theorem; D001682:Biological Availability; D002180:Candidiasis, Oral / Q000209:etiology / Q000517:prevention & control; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D015658:HIV Infections / Q000150:complications / Q000378:metabolism*; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008954:Models, Biological; D013785:Thailand; D013997:Time Factors
D000935:Antifungal Agents; C084794:hydroxyitraconazole; D017964:Itraconazole